Immediate initiation of interferon beta-1b in patients with a first event suggestive of multiple sclerosis (MS) significantly reduces the risk of permanent neurologic impairment compared with delayed initiation, according to findings from the BENEFIT study presented during the AAN's 59th annual meeting.
Immediate initiation of interferon beta-1b in patients with a first event suggestive of multiple sclerosis (MS) significantly reduces the risk of permanent neurologic impairment compared with delayed initiation, according to Mark S. Freedman, MD, professor of neurology, University of Ottawa, Ontario, Canada.
"Initiation of interferon beta-1b early after the first demyelinating event delays and reduces the risk for recurrent disease activity leading to a diagnosis of MS," Dr Freedman said at the American Academy of Neurology 59th Annual Meeting, April 28 to May 5, 2007, in Boston, Massachusetts.
The standard disease management approach for MS has involved delaying treatment until after a patient has >1 clinical attack suggestive of MS, rather than initiating treatment after the first attack, which gives physicians greater assurance of a definite diagnosis of MS. The new data, from phase 2 of the Betaseron in Newly Emerging Multiple Sclerosis For Initial Treatment (BENEFIT) study, counter this philosophy, Dr Freedman said.
Phase 2 was a prospectively planned follow-up period designed to assess the impact of immediate versus delayed treatment with interferon beta-1b on the long-term course of the disease (total observation time, 5 years). All patients who reached the end of the placebo-controlled study were offered interferon beta-1b. At the end of 3 years, 73% of patients were taking interferon beta-1b after the first event suggestive of MS.
Neurologic impairment was measured using the Expanded Disability Status Scale (EDSS). Confirmed EDSS progression over 3 years occurred in 34% of patients randomized to delayed treatment compared with 18% of patients randomized to immediate treatment, corresponding to a 40% relative risk reduction (P=.0218). At 3 years, immediate treatment was associated with a 41% lower likelihood of progression to clinically definite MS compared with delayed treatment (P=.0011), confirming the findings of the placebo-controlled phase.
Early treatment also had a significant effect on the development of gadolinium-enhancing lesions and was associated with a greater reduction in the relapse rate compared with delayed treatment, Dr Freedman said.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More